TABLE 2.
Recommendation for priority of further research of potential agents to diminish or prevent cognitive side effects in electroconvulsive therapy, based on qualitative synthesis and meta‐analysis of the systematic literature review
Recommendation for further study | Intervention | Effect size | Quality of evidence (GRADE) |
---|---|---|---|
High priority | Memantine | Large | Low |
Liothyronine | Medium | Low | |
Medium priority | Acetylcholine inhibitors | None to large | Very low |
Melatonin | Medium to large | Very low | |
Piracetam | None to large | Very low | |
Interventions targeting cortisol Pathway a |
|||
Myo‐inositol a | |||
Adrenergic antagonists a | |||
Calcium antagonists a | |||
Vasopressin analogues a | |||
Opioid receptor antagonists a | |||
Low priority | Ketamine | None | Very low |
Anti‐inflammatory herbal preparations | None | Very low | |
Opioid receptor agonists | None | Low |
No effect size or GRADE was calculated since studies did not meet criteria for inclusion in meta‐analysis.